Xigduo XR is a fixed-dose oral combination of dapagliflozin and extended-release metformin hydrochloride used as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus in adults and pediatric patients aged 10 years and older. It combines an SGLT2 inhibitor with a biguanide. U.S. initial approval was in 2014.
Analysis shows around a third of 54 drugs on TrumpRx.gov are cheaper in the UK, while the platform offers significant savings primarily for obesity and fertility drugs not typically covered by insurance.
The Trump administration launched TrumpRx.gov in February 2026, offering discounted prices on dozens of brand-name prescription drugs through negotiated deals with pharmaceutical companies, though critics warn many listed drugs have cheaper generic alternatives.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02722239 |
An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions |
COMPLETED | PHASE1 |
